尤瑞克林对急性脑梗死患者血浆内皮素—1的影响

目的探讨注射用尤瑞克林对急性脑梗死患者血浆内皮素-1的影响。方法根据1995年第四届全国脑血管病会议制订的诊断标准，选取急性脑梗死患者100例，对照组50例，予缺血性脑卒中基础治疗，治疗组50例，除给予基础治疗外，予注射用尤瑞克林0．15PNA，分别于治疗前及治疗14d行内皮素-1浓度测定及NIHSS评分。结果治疗组和对照组患者在治疗前血浆ET-1浓度及NIHSS评分无显著性差异，但治疗14d后．治疗组ET-1浓度及NIHSS评分均较对照组显著降低。结论尤瑞克林较基础治疗更显著降低急性脑梗死患者血浆ET-1浓度，其治疗作用部分可能是通过降低脑梗死患者体内ET-1的产生而发挥作用。

Influence of urinary kaUidinogenase on plasma endothelin-1 of patients with acute cerebral infarction

Objective To explore the Influence of urinary kallidinogenase on plasma endothelin-1 of patients with acute cerebral infarction. Methods According to the diagnostic criteria developed by the 1995 Fourth National Conference on cerebrovascular disease, 100 patients with acute cerebral infarction were randomly divided into two groups. 50 patients in control group were treated with basic therapy, while 50 cases in treatment group were treated with urinary kallidinogenase injection 0.15 PNA and basic therapy. Plasma endothelin-1 concentration was mesured before treat- ment, 14 days after treatment respectively, and NIHSS score was evaluated at the same time. Results There was no significant difference of plasma endothelin-1 concentration and NIHSS score between control group and treatment group before treatment. While after treatment 14 d, plasma endothelin-1 concentration and NIHSS score in treatment group decreased significantly than that in control group. Conclusion Plasma endothelin-1 concentration in patients with acute cerebral infarction could be significantly lowered by Urinary Kallidinogenase injection than that of basic therapy. Lowered plasma endothelin-1 concentration might be involved in the efficacy of Urinary Kallidinogenase injection.